Analyst Consensus ?
ConsensusBuy49 ratings
Bullish3469.4%
Neutral1530.6%
Bearish00.0%
Regeneron Pharmaceuticals, Inc. · REGN · FY2025 Q2 · Calendar Q3 2025
Regeneron Q2 2025: Strong products, lower guidance
Regeneron's Q2 2025 showed strong commercial momentum from Dupixent, Libtayo and EYLEA HD, alongside pipeline progress led by Lynozyfic. The case is tempered by lower 2025 guidance, Catalent-related regulatory delays, and competitive and pricing pressure around EYLEA.
Reported Before market openNASDAQHealthcare
$76.45B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$12.89
Consensus $8.43
EPS surprise
+52.9%
Reported versus consensus
Reported revenue
$3.68B
Consensus $3.29B
Revenue surprise
+11.8%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+2.5%
Event window
SPY move
-1.6%
Same window
Abnormal move
+4.1%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+3.9%
Up to 20 sessions
REGNSPY benchmark
Ask FN2 about REGN FY2025 Q2
Transcript, numbers and history already loaded
Why did REGN rise 2.5% after beating EPS estimates in FY2025 Q2?What changed in REGN's guidance and outlook in FY2025 Q2?Give me the bull and bear case for REGN after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The quarter added Lynozyfic approval and further Dupixent expansion while highlighting a $7 billion U.S. manufacturing plan. At the same time, management lowered the 2025 outlook, and a Catalent site inspection delayed EYLEA HD enhancements and the odronextamab BLA.
Guidance delta
Management's guidance sentiment moved lower as revised expense assumptions reduced the 2025 outlook.
Key takeaways
- Dupixent, Libtayo and EYLEA HD provided commercial momentum.
- Lynozyfic approval and bispecific-antibody data strengthened the pipeline case.
- Management highlighted a $7 billion U.S. manufacturing expansion and continued internal R&D.
- Catalent-related regulatory delays and lower guidance temper the otherwise strong quarter.
Management priorities
- Expand Dupixent indications and commercial reach.
- Advance Libtayo, Lynozyfic, odronextamab and the broader bispecific pipeline.
- Progress obesity GLP-1/GIP programs and other pipeline candidates.
- Expand U.S. manufacturing and fill/finish capacity.
Follow REGN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$750.95Current
$584Low
$848.41Average
$1,292High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 9, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Buy | Buy | Maintain | Oct 7, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 7, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 6, 2026 |
| Jefferies | Buy | Buy | Maintain | Oct 1, 2026 |
| Argus Research | Buy | Hold | Upgrade | Oct 1, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Sep 29, 2026 |
| HSBC | Buy | Buy | Maintain | Sep 10, 2026 |
| Leerink Partners | Market Perform | Market Perform | Maintain | Aug 17, 2026 |
| Guggenheim | Buy | Buy | Maintain | Aug 3, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 3, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 9, 2026 |
| Benchmark | Buy | Hold | Upgrade | Jul 7, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | May 19, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | May 18, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 30, 2026 |
| TD Cowen | Buy | Buy | Maintain | Apr 23, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Feb 2, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jan 22, 2026 |
| B of A Securities | Buy | Underperform | Upgrade | Jan 7, 2026 |
| Scotiabank | Sector Perform | Sector Perform | Maintain | Nov 24, 2025 |
| UBS | Neutral | Neutral | Maintain | Nov 7, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 30, 2025 |
| Baird | Neutral | Neutral | Maintain | Apr 30, 2025 |
| Raymond James | Outperform | Market Perform | Upgrade | Nov 3, 2023 |
| EF Hutton | Buy | Buy | Maintain | May 1, 2023 |
| SVB Leerink | Outperform | Market Perform | Upgrade | Mar 27, 2023 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Jan 30, 2023 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Nov 5, 2021 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 23, 2021 |
| SunTrust Robinson Humphrey | Buy | Hold | Upgrade | Jul 9, 2020 |
| CFRA | Hold | Hold | Maintain | May 27, 2020 |
| Argus | Hold | Buy | Downgrade | Jun 18, 2019 |
| Leerink Swann | Outperform | Outperform | Maintain | Feb 9, 2018 |
| BTIG Research | Neutral | Buy | Downgrade | Feb 9, 2018 |
| BTIG | Neutral | Buy | Downgrade | Feb 9, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 13, 2017 |
| PiperJaffray | Overweight | Neutral | Upgrade | Feb 13, 2017 |
| Chardan Capital | Neutral | Sell | Upgrade | Dec 12, 2016 |
| Roth Capital | Buy | Buy | Maintain | Apr 4, 2016 |
| Gabelli & Co. | Buy | Buy | Maintain | Mar 15, 2016 |
| Brean Capital | Buy | Buy | Maintain | Feb 10, 2016 |
| Bank of America | Buy | Buy | Maintain | Nov 21, 2014 |
| Argus Capital | Buy | Buy | Maintain | Jul 21, 2014 |
| Lazard | Buy | Buy | Maintain | Sep 13, 2013 |
| JMP Securities | Perform | Market Perform | Maintain | Mar 28, 2013 |
| Bank oferica | Buy | Buy | Maintain | May 29, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $750.95. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Brian Abrahams | $810 | $730.08 | +7.9% | Oct 8, 2026 |
| Raymond James | Chris Raymond | $911 | $742.12 | +21.3% | Oct 8, 2026 |
| Truist Financial | Analyst unavailable | $780 | $747.51 | +3.9% | Oct 7, 2026 |
| Morgan Stanley | Analyst unavailable | $779 | $743.6 | +3.7% | Oct 7, 2026 |
| Jefferies | Analyst unavailable | $930 | $741.16 | +23.8% | Oct 1, 2026 |
| BMO Capital | Evan David Seigerman | $920 | $741.41 | +22.5% | Oct 1, 2026 |
| Argus Research | Analyst unavailable | $850 | $758.27 | +13.2% | Oct 1, 2026 |
| HSBC | Rajesh Kumar | $920 | $807.65 | +22.5% | Sep 10, 2026 |
| Leerink Partners | David Risinger | $824 | $803.48 | +9.7% | Aug 17, 2026 |
| Bernstein | Jeffrey Walch | $756 | $799.46 | +0.7% | Aug 14, 2026 |
| Guggenheim | Analyst unavailable | $1,030 | $763.51 | +37.2% | Aug 3, 2026 |
| RBC Capital | Analyst unavailable | $737 | $739.5 | -1.9% | Jul 31, 2026 |
| Morgan Stanley | Analyst unavailable | $758 | $738.82 | +0.9% | Jul 31, 2026 |
| Cantor Fitzgerald | Carter Gould | $795 | $742.59 | +5.9% | Jul 31, 2026 |
| Robert W. Baird | Analyst unavailable | $761 | $738.34 | +1.3% | Jul 31, 2026 |
| Wells Fargo | Analyst unavailable | $750 | $738.34 | -0.1% | Jul 31, 2026 |
| Guggenheim | Yatin Suneja | $1,000 | $675.72 | +33.2% | Jul 21, 2026 |
| Piper Sandler | Biren Amin | $854 | $662.88 | +13.7% | Jul 9, 2026 |
| Morgan Stanley | Terence Flynn | $730 | $676.23 | -2.8% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $769 | $670.54 | +2.4% | Jul 7, 2026 |
| HSBC | Analyst unavailable | $800 | $643 | +6.5% | Jul 6, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $750 | $654.27 | -0.1% | Jul 6, 2026 |
| Canaccord Genuity | John Newman | $875 | $629.68 | +16.5% | May 19, 2026 |
| Wolfe Research | Alexandria Hammond | $860 | $629.36 | +14.5% | May 18, 2026 |
| Evercore ISI | Analyst unavailable | $825 | $619.84 | +9.9% | May 18, 2026 |
| RBC Capital | Analyst unavailable | $707 | $619.62 | -5.9% | May 18, 2026 |
| Truist Financial | Analyst unavailable | $778 | $619.95 | +3.6% | May 18, 2026 |
| BMO Capital | Analyst unavailable | $730 | $698.25 | -2.8% | May 18, 2026 |
| Piper Sandler | Analyst unavailable | $855 | $698.25 | +13.9% | May 18, 2026 |
| Leerink Partners | Market Perform | $641 | $698.25 | -14.6% | May 18, 2026 |
| Guggenheim | Yatin Suneja | $995 | $707.06 | +32.5% | May 1, 2026 |
| Morgan Stanley | Terence Flynn | $788 | $703.18 | +4.9% | Apr 30, 2026 |
| Truist Financial | Analyst unavailable | $796 | $692.75 | +6.0% | Apr 30, 2026 |
| Barclays | Analyst unavailable | $917 | $686.36 | +22.1% | Apr 30, 2026 |
| Raymond James | Chris Raymond | $910 | $746.58 | +21.2% | Apr 22, 2026 |
| Morgan Stanley | Analyst unavailable | $796 | $746.15 | +6.0% | Apr 10, 2026 |
| Bernstein | Analyst unavailable | $921 | $775.53 | +22.6% | Apr 8, 2026 |
| Truist Financial | Greg Renza | $818 | $770.32 | +8.9% | Mar 9, 2026 |
| Barclays | Eliana Merle | $923 | $764.93 | +22.9% | Mar 6, 2026 |
| RBC Capital | Brian Abrahams | $765 | $784.06 | +1.9% | Mar 2, 2026 |
| Guggenheim | Analyst unavailable | $975 | $785.51 | +29.8% | Feb 9, 2026 |
| Cantor Fitzgerald | Carter Gould | $800 | $757.59 | +6.5% | Feb 2, 2026 |
| Robert W. Baird | Brian Skorney | $742 | $755.34 | -1.2% | Feb 2, 2026 |
| Oppenheimer | Analyst unavailable | $865 | $741.45 | +15.2% | Feb 2, 2026 |
| Tudor Pickering | William Pickering | $925 | $753.13 | +23.2% | Feb 2, 2026 |
| Morgan Stanley | Terence Flynn | $769 | $741.45 | +2.4% | Feb 1, 2026 |
| Raymond James | Analyst unavailable | $870 | $741.45 | +15.9% | Jan 30, 2026 |
| Tudor Pickering | William Pickering | $916 | $762.1 | +22.0% | Jan 27, 2026 |
| RBC Capital | Brian Abrahams | $745 | $769.05 | -0.8% | Jan 27, 2026 |
| Bernstein | Analyst unavailable | $916 | $762.65 | +22.0% | Jan 27, 2026 |
| Evercore ISI | Analyst unavailable | $875 | $761.56 | +16.5% | Jan 22, 2026 |
| Goldman Sachs | Analyst unavailable | $914 | $812.27 | +21.7% | Jan 8, 2026 |
| Leerink Partners | Andrew Berens | $873 | $746.36 | +16.3% | Dec 17, 2025 |
| Morgan Stanley | Terence Flynn | $768 | $741.52 | +2.3% | Dec 12, 2025 |
| HSBC | Analyst unavailable | $985 | $692.58 | +31.2% | Dec 10, 2025 |
| BMO Capital | Evan Seigerman | $850 | $723.67 | +13.2% | Dec 4, 2025 |
| Canaccord Genuity | Analyst unavailable | $1,057 | $723.67 | +40.8% | Dec 4, 2025 |
| Truist Financial | Analyst unavailable | $798 | $766.5 | +6.3% | Nov 24, 2025 |
| Scotiabank | Analyst unavailable | $770 | $769.23 | +2.5% | Nov 24, 2025 |
| HSBC | Analyst unavailable | $890 | $755.9 | +18.5% | Nov 24, 2025 |
| Wells Fargo | Mohit Bansal | $700 | $702.75 | -6.8% | Nov 20, 2025 |
| RBC Capital | Analyst unavailable | $708 | $653.01 | -5.7% | Oct 29, 2025 |
| Cantor Fitzgerald | Carter Gould | $740 | $657 | -1.5% | Oct 29, 2025 |
| BMO Capital | Evan Seigerman | $725 | $654.48 | -3.5% | Oct 29, 2025 |
| Wells Fargo | Analyst unavailable | $615 | $654.48 | -18.1% | Oct 29, 2025 |
| Robert W. Baird | Analyst unavailable | $637 | $645.93 | -15.2% | Oct 29, 2025 |
| Bernstein | Analyst unavailable | $818 | $654.42 | +8.9% | Oct 29, 2025 |
| Guggenheim | Analyst unavailable | $865 | $654.48 | +15.2% | Oct 29, 2025 |
| Robert W. Baird | Brian Skorney | $630 | $654.48 | -16.1% | Oct 29, 2025 |
| Raymond James | Christopher Raymond | $723 | $654.48 | -3.7% | Oct 28, 2025 |
| Morgan Stanley | Analyst unavailable | $767 | $654.48 | +2.1% | Oct 28, 2025 |
| Morgan Stanley | Analyst unavailable | $756 | $568.81 | +0.7% | Oct 10, 2025 |
| Raymond James | Christopher Raymond | $673 | $577.9 | -10.4% | Sep 2, 2025 |
| BMO Capital | Analyst unavailable | $640 | $571.54 | -14.8% | Aug 4, 2025 |
| Citigroup | Geoff Meacham | $650 | $563.43 | -13.4% | Aug 1, 2025 |
| UBS | Trung Huynh | $584 | $559.76 | -22.2% | Jul 11, 2025 |
| Morgan Stanley | Terence Flynn | $754 | $560.28 | +0.4% | Jul 10, 2025 |
| Morgan Stanley | Terence Flynn | $755 | $490.81 | +0.5% | Jun 2, 2025 |
| Cantor Fitzgerald | Carter Gould | $695 | $585.49 | -7.5% | Apr 22, 2025 |
| Canaccord Genuity | John Newman | $850 | $585.49 | +13.2% | Apr 22, 2025 |
| BMO Capital | Analyst unavailable | $903 | $666.87 | +20.2% | Mar 14, 2025 |
| BMO Capital | Evan David Seigerman | $1,190 | $843.6 | +58.5% | Nov 1, 2024 |
| Piper Sandler | Christopher Raymond | $1,195 | $843.6 | +59.1% | Nov 1, 2024 |
| Leerink Partners | Andrew Berens | $880 | $843.6 | +17.2% | Nov 1, 2024 |
| Evercore ISI | Cory Kasimov | $1,170 | $838.2 | +55.8% | Oct 31, 2024 |
| Evercore ISI | Cory Kasimov | $1,175 | $941.39 | +56.5% | Oct 24, 2024 |
| Wells Fargo | Mohit Bansal | $1,050 | $962.34 | +39.8% | Oct 23, 2024 |
| Truist Financial | Thomas Klee | $1,200 | $1,091.98 | +59.8% | Sep 24, 2024 |
| Leerink Partners | David Risinger | $1,077 | $1,091.98 | +43.4% | Sep 24, 2024 |
| Robert W. Baird | Brian Skorney | $940 | $1,091.98 | +25.2% | Sep 24, 2024 |
| Goldman Sachs | Salveen Richter | $1,292 | $1,091.98 | +72.0% | Sep 24, 2024 |
| BMO Capital | Evan David Seigerman | $1,300 | $1,159.94 | +73.1% | Sep 12, 2024 |
| RBC Capital | Brian Abrahams | $1,282 | $1,139.41 | +70.7% | Sep 9, 2024 |
| Raymond James | Christopher Raymond | $1,242 | $1,187.66 | +65.4% | Aug 23, 2024 |
| Bank of America Securities | Geoff Meacham | $805 | $1,077.48 | +7.2% | Aug 2, 2024 |
| RBC Capital | Brian Abrahams | $1,240 | $1,093.14 | +65.1% | Aug 2, 2024 |
| Raymond James | Christopher Raymond | $1,166 | $1,063.6 | +55.3% | Jul 19, 2024 |
| Guggenheim | Yatin Suneja | $1,180 | $1,085.62 | +57.1% | Jul 18, 2024 |
| UBS | Trung Huynh | $1,250 | $1,092.31 | +66.5% | Jul 12, 2024 |
| Morgan Stanley | Terence Flynn | $1,182 | $1,071.12 | +57.4% | Jul 11, 2024 |
| Argus Research | Jasper Hellweg | $1,170 | $1,063.89 | +55.8% | Jun 25, 2024 |
| RBC Capital | Brian Abrahams | $1,299 | $1,022.03 | +73.0% | Jun 13, 2024 |
| RBC Capital | Brian Abrahams | $1,229 | $1,010.54 | +63.7% | Jun 12, 2024 |
| RBC Capital | Brian Abrahams | $1,200 | $998.64 | +59.8% | Jun 4, 2024 |
| BMO Capital | Evan David Seigerman | $1,082 | $992.47 | +44.1% | Jun 3, 2024 |
| Raymond James | Christopher Raymond | $1,000 | $982.29 | +33.2% | May 20, 2024 |
| Evercore ISI | Cory Kasimov | $1,150 | $976.96 | +53.1% | May 13, 2024 |
| RBC Capital | Brian Abrahams | $1,185 | $937.61 | +57.8% | May 3, 2024 |
| Jefferies | Akash Tewari | $1,060 | $911.78 | +41.2% | Apr 12, 2024 |
| RBC Capital | Brian Abrahams | $1,189 | $921.34 | +58.3% | Apr 11, 2024 |
| Morgan Stanley | Matthew Harrison | $1,115 | $965.47 | +48.5% | Mar 13, 2024 |
| BMO Capital | Brian Abrahams | $1,076 | $934.06 | +43.3% | Jan 12, 2024 |
| RBC Capital | Brian Abrahams | $1,076 | $933.2 | +43.3% | Jan 12, 2024 |
| Leerink Partners | Andrew Berens | $976 | $820 | +30.0% | Mar 27, 2023 |
| Jefferies | Akash Tewari | $925 | $819.68 | +23.2% | Mar 24, 2023 |
| EF Hutton | Analyst unavailable | $853 | $769.94 | +13.6% | Feb 8, 2023 |
| RBC Capital | Analyst unavailable | $787 | $786.94 | +4.8% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $883 | $783.13 | +17.6% | Feb 6, 2023 |
| Leerink Partners | Analyst unavailable | $834 | $783.13 | +11.1% | Feb 6, 2023 |
| Guggenheim | Analyst unavailable | $915 | $707.63 | +21.8% | Nov 11, 2022 |
| Goldman Sachs | Analyst unavailable | $970 | $726.93 | +29.2% | Oct 3, 2022 |
| Canaccord Genuity | Analyst unavailable | $750 | $710.21 | -0.1% | Sep 16, 2022 |
| Piper Sandler | Analyst unavailable | $775 | $701.15 | +3.2% | Sep 13, 2022 |
| Wells Fargo | Analyst unavailable | $800 | $718.82 | +6.5% | Sep 12, 2022 |
| Barclays | Analyst unavailable | $815 | $708.85 | +8.5% | Sep 9, 2022 |
| Morgan Stanley | Matthew Harrison | $851 | $708.85 | +13.3% | Sep 9, 2022 |
| Jefferies | Akash Tewari | $675 | $708.85 | -10.1% | Sep 8, 2022 |
| Morgan Stanley | Matthew Harrison | $625 | $628.71 | -16.8% | Aug 15, 2022 |
| BMO Capital | Analyst unavailable | $788 | $614.96 | +4.9% | Aug 4, 2022 |
| Morgan Stanley | Analyst unavailable | $619 | $604.3 | -17.6% | Jul 15, 2022 |
| RBC Capital | Kennen MacKay | $638 | $597.62 | -15.0% | Jun 29, 2022 |
| Wells Fargo | Mohit Bansal | $735 | $571.81 | -2.1% | Jun 11, 2022 |
| Morgan Stanley | Analyst unavailable | $610 | $626.94 | -18.8% | Jun 3, 2022 |
| Argus Research | Analyst unavailable | $760 | $683.02 | +1.2% | May 31, 2022 |
| Leerink Partners | Geoffrey Porges | $738 | $680.22 | -1.7% | May 23, 2022 |
| Credit Suisse | Lorenzo Biasio | $725 | $681.91 | -3.5% | May 23, 2022 |
| Morgan Stanley | Analyst unavailable | $620 | $638.13 | -17.4% | May 5, 2022 |
| Barclays | Carter Gould | $745 | $733.02 | -0.8% | Apr 16, 2022 |
| BMO Capital | Evan David Seigerman | $780 | $638.41 | +3.9% | Feb 13, 2022 |
| Barclays | Carter Gould | $700 | $622.36 | -6.8% | Feb 7, 2022 |
| RBC Capital | Kennen MacKay | $679 | $622.96 | -9.6% | Feb 4, 2022 |
| Cowen & Co. | Tyler Van Buren | $640 | $622.96 | -14.8% | Feb 4, 2022 |
| J.P. Morgan | Cory Kasimov | $604 | $622.96 | -19.6% | Feb 4, 2022 |
| Evercore ISI | Joshua Schimmer | $680 | $622.85 | -9.4% | Feb 2, 2022 |
| Morgan Stanley | Matthew Harrison | $585 | $611.22 | -22.1% | Jan 18, 2022 |
| Bernstein | Aaron Gal | $660 | $627.1 | -12.1% | Jan 3, 2022 |
| Goldman Sachs | Salveen Richter | $824 | $625 | +9.7% | Dec 6, 2021 |
| Cantor Fitzgerald | Alethia Young | $760 | $622.2 | +1.2% | Nov 10, 2021 |
| UBS | Esther Rajavelu | $763 | $646.11 | +1.6% | Sep 9, 2021 |
| Argus Research | Jasper Hellweg | $590 | $528.75 | -21.4% | Jun 14, 2021 |
| Canaccord Genuity | John Newman | $700 | $506.72 | -6.8% | May 21, 2021 |
Track every rating change on REGN the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationRegeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients.…
Historical context
All REGN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
Get the REGN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-09T14:40:45.799779+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-09T14:40:45.797011+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-09. For educational purposes only; not investment advice.